A national audit of pollen immunotherapy for children in the United Kingdom: patient selection and programme safety

Vance, Gillian; Goldring, Steven R.; Warner, John O.; Cox, Helen; Sihra, B.S.; Hughes, S.; Gardner, Janelle; North, JR A. Frederick; Roberts, Graham; Proudfoot, CW; Clarke, A.; Luyt, David; Gillies, Douglas; A, Fox

doi:10.1111/j.1365-2222.2011.03803.x

Cited by 11 publications

(10 citation statements)

References 41 publications

(60 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Subcutaneous injection immunotherapy has been associated with systemic reactions but it is generally well tolerated in children (128,129). There are also some nonblinded data to suggest that SCIT may alter the natural history of allergic disease in childhood (130).…”

Section: Subcutaneous Injection Immunotherapy (Scit)mentioning

confidence: 99%

“…Two commercial grass products have received European market authorization for patients at least 5 years of age (138,139). Local oral reactions are experienced in up to three quarter of the patients but are mild to moderate, self-resolve after a few minutes and usually disappear after a few weeks therapy (129,134,140,141). Severe adverse reactions have been seen but are very rare (142).…”

Section: Sublingual Immunotherapy (Slit)mentioning

confidence: 99%

See 1 more Smart Citation

Paediatric rhinitis: position paper of the European Academy of Allergy and Clinical Immunology

Roberts

Xatzipsalti

Borrego

et al. 2013

Allergy

Self Cite

315

248

View full text Add to dashboard Cite

Rhinitis is a common problem in childhood and adolescence and impacts negatively on physical, social and psychological well-being. This position paper, prepared by the European Academy of Allergy and Clinical Immunology Taskforce on Rhinitis in Children, aims to provide evidence-based recommendations for the diagnosis and therapy of paediatric rhinitis. Rhinitis is characterized by at least two nasal symptoms: rhinorrhoea, blockage, sneezing or itching.

show abstract

Section: Subcutaneous Injection Immunotherapy (Scit)mentioning

confidence: 99%

Section: Sublingual Immunotherapy (Slit)mentioning

confidence: 99%

Paediatric rhinitis: position paper of the European Academy of Allergy and Clinical Immunology

Roberts

Xatzipsalti

Borrego

et al. 2013

Allergy

Self Cite

315

248

View full text Add to dashboard Cite

show abstract

“…Local adverse reactions in SLIT were reported in almost half of the children. Only 3 % interrupted AIT because of AE [28].…”

Section: Safety Of Pediatric Scitmentioning

confidence: 95%

Allergic Sensitization and Rhinitis in Children: What Is New?

Larenas‐Linnemann

2015

Curr Treat Options Allergy

View full text Add to dashboard Cite

Allergic rhinitis I Pediatric I House dust mite I Pollens I Skin prick test I Immunotherapy Opinion statement In children with nasal symptoms during several months, oftentimes with a chronically relapsing course, allergic rhinitis is one of the most probable diagnoses. This is often complicated with recurrent respiratory infections, as there is a circular causal loop between allergic rhinitis that increases the frequency of respiratory infections and the infections that exacerbate the allergic disease. As a consequence, in these children, the physician should intentionally search for allergic sensitization, in serologic specific IgE testing and/or with skin prick testing. If a possible allergic diathesis is further suspected because of a personal (atopic dermatitis) or a family history of allergic diseases, the search for allergic sensitization should begin at an even earlier age; in several cases, allergic sensitization can already be shown even before the age of two. In my opinion, in highly atopic children as soon as a specific allergic sensitization can be documented that coincide with the presence of symptoms on possible exposure, as obtained from the detailed history, allergen immunotherapy should be offered as an integral part of the treatment. It is very well plausible that the earlier in the development of the allergic disease, we can redirect the immune system, the better the results. However, in these young allergic children, I only choose sublingual immunotherapy (SLIT), being the option with the best safety profile. In our clinic, we have looked for several ways to improve adherence, which is an issue especially in SLIT. Among the several strategies we implemented are written information on the treatment and the administration schedule with a 20 min explanation by a specialized nurse at start, a flexible, 1-month up-dosing phase to reduce the frequency and intensity of local side effects and reduce the frequently seen flare in nasal symptoms, morning dosing, up-dosing under the cover of an antihistamine and a topical corticosteroid in the evening for 6 weeks, a close follow-up of the children by phone contacts, and an initial follow-up visit at 6 weeks.

show abstract

“…In this regard, Vance et al. 's audit of current immunotherapy practice is useful . It revealed that few children are currently treated with SCIT or SLIT in the United Kingdom, although it is well tolerated.…”

Section: Clinical Allergymentioning

confidence: 99%

“…Again, the evidence for efficacy is not as strong as in adult, but both SCIT and SLIT seem effective and safe in children when used to treat AR with or without asthma. In this regard, Vance et al's audit of current immunotherapy practice is useful [146]. It revealed that few children are currently treated with SCIT or SLIT in the United Kingdom, although it is well tolerated.…”

Section: Immunotherapymentioning

confidence: 99%

Developments in the field of allergy in 2011 through the eyes of Clinical and Experimental Allergy

Arshad

Dharmage

Ferreira

et al. 2012

Clin Experimental Allergy

View full text Add to dashboard Cite

As in previous years, we felt it would be of value to our readership to summarize the new information provided by the authors who have published in Clinical and Experimental Allergy in 2011 and set this in the context of recent advances in our understanding of the pathogenesis and management of allergic disease in all its many manifestations. In 2011, about 210 articles were published in Clinical and Experimental Allergy including editorials, reviews, opinion articles, guidelines, letters, book reviews and of course at the heart of the journal, papers containing original data. As before, this review is divided into sections based on the way the journal is structured, although this year we have grouped together all the papers dealing with mechanisms of allergic disease, whether they involve patients (clinical mechanisms), pure in vitro studies (basic mechanisms) or animal models (experimental models), as we felt this was a more coherent way to deal with the subject. In the field of asthma and rhinitis, the relationship between airway inflammation and airway dysfunction was of perennial interest to investigators, as were phenotypes and biomarkers. Aspirin hypersensitivity appeared in studies in several papers and there was new interest in asthma in the elderly. The mechanisms involved in allergic disease describe advances in our understanding of T cell responses, the relationship between inflammation and disease, mast cell and basophil activation, steroid resistance and novel therapies. In the section dealing with epidemiology, studies seeking to identify risk factors for allergic disease including vitamin D are prominent, as once again are studies investigating gene-environment interactions. The clinical allergy section focuses on drug allergy, food allergy and immunotherapy. The area of oral immunotherapy for food allergy is well covered and we were grateful to Stephen Durham for guest editing an outstanding special issue on immunotherapy in the centenary year of Leonard Noon's pioneering work. Lastly, in the field of allergens, the interest in component-resolved diagnosis continues to grow and there are also articles describing important novel cultivars and the effect of food processing on the allergenic properties of foods. Another terrific year, full of important and high-quality work,which the journal has been proud to bring to the allergy community.

show abstract

A national audit of pollen immunotherapy for children in the United Kingdom: patient selection and programme safety

Cited by 11 publications

References 41 publications

Paediatric rhinitis: position paper of the European Academy of Allergy and Clinical Immunology

Paediatric rhinitis: position paper of the European Academy of Allergy and Clinical Immunology

Allergic Sensitization and Rhinitis in Children: What Is New?

Developments in the field of allergy in 2011 through the eyes of Clinical and Experimental Allergy

Contact Info

Product

Resources

About